Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326780 · ClinicalTrials.gov registry record · Phase 2
A Study of a New Drug Treatment for Acne
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 431
- Enrollment target
NCT01326780 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 431 participants.
The verdict
NCT01326780, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 431 participants
- Enrollment target
Study Summary
A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.
Interventions
- DRUG 1.2% JNJ 10229570-AAA
- DRUG 2.4% JNJ 10229570-AAA
- DRUG 3.6% JNJ 10229570-AAA
- OTHER Vehicle control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 431 participants |
| Start Date | 2011-03-31 |
| Est. Completion | 2012-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01326780
The ClinicalTrials.gov registry entry for NCT01326780 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 431 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 1.2% JNJ 10229570-AAA is the first listed.
NCT01326780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01326780 about?
NCT01326780 is a clinical study titled "A Study of a New Drug Treatment for Acne". A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.
What is the current status of trial NCT01326780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 431 participants. The study started on 2011-03-31. Estimated completion is 2012-03-31.
What interventions are being tested in trial NCT01326780?
The interventions under investigation include: 1.2% JNJ 10229570-AAA (DRUG), 2.4% JNJ 10229570-AAA (DRUG), 3.6% JNJ 10229570-AAA (DRUG), Vehicle control (OTHER).
Who is sponsoring clinical trial NCT01326780?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.